Table 1.
Overview of response rates and downstaging success rates with 90Y-RE in patients with HCC
| Author | Year | N | mRECIST (%) | WHO (%) | EASL (%) | Downstaging success rate | Median time to response/downstaging | Resection or RFA | LTX | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR | PR | CR | PR | CR | PR | % | Months (range) | %e | %e | |||
| Kulika [49] | 2006 | 34 | – | – | – | 50 | – | – | 67 | 4 (1.9–16.3) | 34 | 23 |
| Heckman [43] | 2008 | 16 | – | – | – | – | – | – | 13 | – | – | 100f |
| Lewandowskia [51] | 2009 | 43 | – | – | 0 | 61 | 47 | 39 | 58 | 3.1 (1.8–8.7) | 42 | 21 |
| Ibrahima [45] | 2012 | 8 | – | – | 13 | 63 | 37 | 50 | 50 | – | – | 37 |
| Iñarrairaegui [6] | 2012 | 21 | – | – | – | – | – | – | 29 | – | 19 | 10 |
| Tohme [57] | 2013 | 20 | 37 | 19 | – | – | – | – | 33 | – | – | 100f |
| Donahueb [108] | 2013 | 12 | – | – | 0 | 50 | 25 | 42 | 8 | (1.4–11.3) | – | 50 |
| Vouche [75] | 2014 | 102 | 47 | 39 | – | – | – | – | – | – | – | 32 |
| Ettorrec [40] | 2014 | 22 | – | – | – | – | – | – | 50 | – | 5 | 45 |
| Kulikd [48] | 2014 | 20 | – | – | – | – | – | – | – | – | 5 | 85 |
| Abdelfattah [36] | 2015 | 9 | – | – | – | – | – | – | 100 | – | – | 100f |
aOverlapping patientpopulations
bProspective study on 90Y-RE in patients with a transjugular intrahepatic portosystemic shunt (TIPS)
cCorrespondence to editor
dProspective randomized pilot study comparing 90Y-RE + Sorafenib with 90Y-RE alone
ePercentage of the total population
f100 % LTX is inherent to retrospective patient study design